Search results
Results from the WOW.Com Content Network
Corneal cross-linking (CXL) with riboflavin (vitamin B 2) and UV-A light is a surgical treatment for corneal ectasia such as keratoconus, PMD, and post-LASIK ectasia. It is used in an attempt to make the cornea stronger. According to a 2015 Cochrane review, there is insufficient evidence to determine if it is useful in keratoconus. [2]
Intrastromal corneal rings were approved in 2004 by the Food and Drug Administration for people with keratoconus who cannot adequately correct their vision with glasses or contact lenses. They were approved under the Humanitarian Device Exemption, [19] [20] which means the manufacturer did not have to demonstrate effectiveness.
In 2016, however, the FDA approved cross-linking surgery as a treatment for keratoconus and recommended that a registry system should be set-up to evaluate the long-term treatment effect. [ 9 ] [ 70 ] The Save Sight Keratoconus Registry is an international database of keratoconus patients that is tracking outcomes of cross-linking in patients ...
(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called ...
They are now mostly used to treat mild to moderate keratoconus. [1] Intrastromal corneal rings were approved in 2004 by the Food and Drug Administration for people with keratoconus who cannot adequately correct their vision with glasses or contact lenses, and for whom corneal transplant is the only other option. [5]
The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company said. ... The FDA's approval is based on data from two trials involving 469 ...
While it was once “just” a medication for people with type 2 diabetes, metformin is now thought of as a “wonder drug with multiple potentials,” says David Cutler, M.D., a family medicine ...
Intacs implants, corneal collagen cross-linking, and corneal transplant surgery are additional options. Surgery is reserved for individuals who do not tolerate contact lenses. The term "pellucid marginal degeneration" was first coined in 1957 by the ophthalmologist Schalaeppi. [ 2 ]